Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P19474

UPID:
RO52_HUMAN

ALTERNATIVE NAMES:
52 kDa Ro protein; 52 kDa ribonucleoprotein autoantigen Ro/SS-A; RING finger protein 81; RING-type E3 ubiquitin transferase TRIM21; Ro(SS-A); Sjoegren syndrome type A antigen; Tripartite motif-containing protein 21

ALTERNATIVE UPACC:
P19474; Q5XPV5; Q96RF8

BACKGROUND:
The protein E3 ubiquitin-protein ligase TRIM21 plays a pivotal role in the ubiquitin-proteasome system, regulating the degradation of key proteins involved in immune signaling and autophagy. It acts as an autophagy receptor and negatively regulates IFN-beta production, highlighting its significance in innate immunity and inflammatory processes. TRIM21's involvement in the regulation of autophagy and immune responses underscores its biological importance.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of E3 ubiquitin-protein ligase TRIM21 offers promising avenues for the development of novel therapeutic interventions, especially in diseases characterized by dysregulated immune responses and autophagy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.